Omega Therapeutics IPO Presentation Deck

In vivo POC Data in Regenerative Medicine Program - HNF4A Improvement in liver histology after IV treatment with 1 or 2 weekly doses of OEC candidate in murine model of fibrosis (CCl4-induced) 1 dose (with continued CC14) 2 doses (with continued CCIA) Ⓒ2021 Omega Therapeutics, Inc. Treated Normal CCIA Controls 24

View entire presentation